AAD requests your feedback on parts two and three of atopic dermatitis guidelines

                 

By Robert Sidbury, MD, MPH

Atopic dermatitis (AD) is one of the most common conditions we see in our offices. At times, though, it can be one of the most challenging to treat. Insights into AD pathogenesis and evolving therapies have altered my understanding of the condition over time.

Since 2011, I've co-chaired an Academy work group charged with updating our previous clinical guidelines of AD care. These guidelines were last published in 2004, and since that time, a great deal of research has been published about AD. Together with my co-chair, Lawrence Eichenfield, MD, and group of dedicated AD experts, we have thoroughly analyzed the new data to develop updated and expanded recommendations for the diagnosis, assessment, and treatment of AD. When they are complete, the Academy will have a four-part, evidence-based guideline series for this condition.

Insights into AD pathogenesis and evolving therapies have altered my understanding of the condition over time.

In June, we asked for your feedback in reviewing part one of this guideline series. This input proved to be valuable in developing part one, which provides for diagnostic criteria, the use of biomarkers, disease, and outcome scales in the clinical setting, and awareness of common clinical associations that affect patients with AD.

Now, we’re requesting your feedback for parts two and three. These parts cover an enormous amount of information related to the management and treatment of AD. Part two focuses on the use of non-pharmacological approaches (moisturizers, bathing practices, wet wraps, etc.,) along with pharmacological modalities (corticosteroids, calcineurin inhibitors, antimicrobials, and antihistamines). Part three focuses on the use of phototherapy and systemic agents, including immunomodulators, antimicrobials, and antihistamines.

From Oct. 25 through Nov. 15, parts two and three of this guideline series will be available for review on the Academy website. If you would like to comment on the guidelines, you will need to follow three steps:

  1. Be sure you have a current conflict of interest disclosure statement on record with the Academy.
  2. Review the draft guideline. (The comment period is now closed).
  3. Send all your comments via email to guidelines@aad.org.

Your input in this process is invaluable, and we look forward to hearing from you.

Robert Sidbury, MD, MPH, is associate professor in the department of pediatrics and chief of the division of dermatology at Seattle Children’s Hospital and the University of Washington School of Medicine.

Email the Member to Member editor at members@aad.org.

Related resources: